Peritumoral infiltration of CD3 lymphocytes makes a difference in prostate cancer
Abstract
Background/Aim. Prostate cancer (PC) is the second most common malignancy in men, and the fifth leading cause of cancer death. The most important prognostic parameters are tumor, node, and metastasis (TNM) status, initial prostate-specific antigen (PSA), Gleason score, and grade group. However, these parameters are insufficient for accurate prediction of the course of the disease. The aim of this study was to examine the prognostic and predictive value of CD3⁺ T lymphocyte infiltration, including the CD8⁺ T-cell subset, in PC tissue across various disease stages. Methods. A prospective cohort study included 90 newly diagnosed patients with PC, divided into three groups [30 with medium/high-risk localized disease (Group A), 30 with locally advanced disease (Group B), and 30 with metastatic disease (Group C)]. The patients were followed for 120 months (10 years). The difference in the density of CD3+ and CD8+ T lymphocytes was analyzed in the tumor tissue (TT) and at the invasive margin (IM). The influence of infiltration of CD3+ T and CD8+ T lymphocytes on progression-free survival (PFS) and overall survival (OS) in patients with PC was analyzed. Lymphocytic infiltration was quantified at the area of greatest density using an optical Leica microscope at ×200 magnification and photographed with a Leica camera. The field of view was 0.226377 mm². Lymphocytes were then manually counted with the aid of commercially available software Aperio 12.0. Correlations with clinical parameters, PFS, and OS were analyzed using receiver operating characteristic (ROC) curves, Kaplan-Meier survival analysis, and correlation coefficients. Results. High peritumoral infiltration of CD3+ lymphocytes was an independent predictor of shorter PFS and OS (log-rank p < 0.001). CD3+ IM infiltration correlated significantly with initial PSA, nadir PSA, and perineural invasion (p < 0.05), while there was no correlation with Gleason score, International Society of Urological Pathology (ISUP) grade, or age. Thresholds of CD3+ IM predictive of cancer-specific mortality [area under the curve (AUC) = 0.681, p = 0.0017], OS (AUC = 0.634, p = 0.0173), and PFS (AUC = 0.657, p = 0.0062) were identified using ROC analysis. No significant prognostic value was found for CD3+ T lymphocyte infiltration in the TT, nor for CD8⁺ T lymphocyte infiltration in either TT or at the IM. Conclusion. CD3+ T lymphocyte infiltration at IM is a significant prognostic and predictive biomarker in PC, indicating tumor aggressiveness and potential influence on treatment response. These findings support the integration of immune profiling into routine histopathological evaluation to refine risk stratification and guide personalized treatment strategies in patients with PC.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229–63.
Andersen LB, Nørgaard M, Rasmussen M, Fredsøe J, Borre M, Ulhøi BP, et al. Immune cell analyses of the tumor microenvi-ronment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J Pathol 2021; 255(2): 155–65.
Soliman SAM, Yassen NN, Abdelaal SE, Shabana ME. Expres-sion of CD3+ and CD8+ tumor-infiltrating lymphocytes in prostatic carcinoma: immunohistochemical study and image analysis. Egypt J Pathol 2024; 44(2): 207–14.
Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, et al. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in pros-tate cancer. Prostate 2014; 74(14): 1452–61.
Zafar MM, Rauf Z, Sohail A, Khan AR, Obaidullah M, Khan SH, et al. Detection of tumour infiltrating lymphocytes in CD3 and CD8 stained histopathological images using a two-phase deep CNN. Photodiagnosis Photodyn Ther 2022; 37: 102676.
Esmail RSEN, Kamal A, Shabana M. Immunoscore As A Pre-dictor Of Disease Recurrences And Patientsâ€TM Survival in Colon Cancer: A Clinicopathologic Study. Open Access Maced J Med Sci 2020; 8(E): 143–9.
Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, et al. EAU-EANM-ESTRO-ESUR-SIOG Pros-tate Cancer Guideline Panel Consensus Statements for De-ferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETEC-TIVE Study). Eur Urol 2019; 76(6): 790–813.
Hammer Ø, Harper DAT, Ryan PD. PAST: Paleontological Statistics Software Package for Education and Data Analysis. Palaeontologia Electronica 2001; 4(1): 1–9.
Statistics Kingdom. Correlation Coefficient Calculator [Inter-net]. Melbourne: Statistics Kingdom [cited 2025 Jun 23; ac-cessed 2025 Aug 28]. Available from: https://www.statskingdom.
com/correlation-calculator.html
Vilaça M, Correia Pinto J, Magalhães H, Reis F, Mesquita A. Tumor-Infiltrating Lymphocytes in Localized Prostate Cancer: Do They Play an Important Role? Cureus 2023; 15(1): e34007.
Davidsson S, Ohlson AL, Andersson SO, Fall K, Meisner A, Fiorentino M, et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal pros-tate cancer. Mod Pathol 2013; 26(3): 448–55.
Yang Y, Attwood K, Bshara W, Mohler JL, Guru K, Xu B, et al. High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radi-cal prostatectomy. Prostate 2021; 81(1): 20–8.
Kärjä V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005; 25(6C): 4435–8.
Richardsen E, Uglehus RD, Due J, Busch C, Busund LT. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology 2008; 53(1): 30–8.
Flammiger A, Bayer F, Cirugeda-Kühnert A, Huland H, Tennstedt P, Simon R, et al. Intratumoral T but not B lymphocytes are re-lated to clinical outcome in prostate cancer. APMIS 2012; 120(11): 901–8.
Molina OE, LaRue H, Simonyan D, Hovington H, Vittrant B, Têtu B, et al. Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes. Front Immunol 2024; 15: 1372837.
